Myricx Bio

Executive Summary

Myricx Bio is a London-based biotechnology company pioneering a novel class of antibody-drug conjugates (ADCs) based on inhibitors of N-myristoyltransferases (NMT). Unlike conventional ADC payloads (e.g., tubulin inhibitors or topoisomerase inhibitors), NMT inhibition targets a fundamental protein lipidation process essential for cancer cell survival, offering a potentially broader therapeutic window and reduced resistance. The company's platform leverages proprietary small molecule NMT inhibitors conjugated to monoclonal antibodies targeting tumor-associated antigens, aiming to deliver potent and selective cytotoxicity. Founded in 2020, Myricx is preclinical and has raised undisclosed funding to advance its lead programs.

Upcoming Catalysts (preview)

• Q4 2026Lead optimization data for first NMT-ADC candidate60% success
• Q1 2027IND-enabling studies initiation50% success
• TBDPotential partnership or licensing deal30% success